Gilead Sciences (GILD) is a $29.4 billion-revenue biopharmaceutical company headquartered in Foster City, California. It dominates the global HIV treatment market with over 50% share in the U.S., generates $10 billion a year in operating cash flow, and carries one of the most durable product franchises in pharmaceuticals: Biktarvy, a single-tablet HIV regimen that produced $14.3 billion in sales in 2025 alone. Beyond HIV, Gilead has a growing oncology business built through acquisition (CAR-T cell therapy via Kite, the antibody-drug conjugate Trodelvy via Immunomedics), a liver disease portfolio, and declining COVID-era revenue from Veklury (remdesivir).
The central tension with Gilead is this: the company literally cured Hepatitis C, watched that franchise collapse from $19 billion in annual revenue to $1.3 billion, and has spent the last decade and over $30 billion in acquisitions trying to build new growth engines that won’t suffer the same fate. In early 2026, it committed another $10 billion in two months, buying Arcellx for CAR-T cell therapy in cancer and Ouro Medicines for a first-in-class autoimmune treatment. Whether those bets pay off will determine if Gilead remains a pharmaceutical powerhouse or becomes the cautionary tale of a one-franchise company that couldn’t diversify fast enough.
From Dengue Fever to Drug Discovery
Gilead was incorporated on June 22, 1987, under the name Oligogen. Michael L. Riordan, a young physician who had contracted dengue fever while working abroad, founded the company to pursue antisense oligonucleotide technology, a then-novel approach to turning off genes associated with disease. The company raised $2 million from Menlo Ventures, recruited Nobel laureates to its scientific advisory board, and renamed itself Gilead Sciences after the biblical “Balm of Gilead,” a reference to healing.
The early years were grim. Gilead had no approved products, no revenue, and nearly ran out of money. It went public in January 1992, raising $86 million in its IPO, but its core antisense platform produced nothing viable. In 1991, the company pivoted toward small-molecule antivirals by licensing nucleotide technology, including tenofovir. That pivot would define the next three decades.
The antiviral bet started paying off across multiple fronts in the mid-to-late 1990s. Gilead’s first approved product, Vistide (cidofovir) for CMV retinitis in AIDS patients, arrived in 1996. That same year, Gilead scientists developed oseltamivir, a neuraminidase inhibitor that blocks influenza virus replication, and licensed it to Roche for a $10 million upfront payment, $40 million in milestones, and tiered royalties of 14% to 22% on net sales. Roche funded clinical development and brought the drug to market as Tamiflu in October 1999. The milestone payments helped fund Gilead’s own HIV pipeline during a critical period when the company was still pre-profit. In 1999, Gilead also acquired NeXstar Pharmaceuticals, gaining an antifungal drug (AmBisome) and a European commercial presence.
The HIV program, though, was where the real money would be. Viread (tenofovir) won FDA approval in 2001, giving Gilead its first foothold in what would become the largest therapeutic market in its history. The following year, Gilead acquired Triangle Pharmaceuticals for $464 million, bringing emtricitabine into the portfolio and setting up the tenofovir/emtricitabine backbone that would underpin nearly every major Gilead HIV product for the next two decades. Triangle also pushed Gilead past a milestone that had seemed unlikely for most of its existence: 2002 was the company’s first profitable year.
In 2006, Gilead launched Atripla, the world’s first complete single-tablet, once-daily HIV regimen. It was a landmark in patient convenience and adherence, and it established the playbook Gilead would follow for the next two decades: combine best-in-class antivirals into simple, elegant dosing regimens that become the standard of care.
The Pharmasset Gamble
Pharmasset was a clinical-stage pharmaceutical company based in Princeton, New Jersey, founded in 1998 by Raymond Schinazi and Dennis Liotta, scientists at Emory University. Its lead compound, PSI-7977, was a nucleotide polymerase inhibitor for Hepatitis C. Gilead had no prior partnership or equity stake in the company. BMS did have a clinical collaboration with Pharmasset, making Gilead the outsider in this story.
What changed everything was a data presentation on November 6, 2011, at the American Association for the Study of Liver Diseases annual meeting in San Francisco. The ELECTRON trial results showed that PSI-7977 plus ribavirin, dosed for just 12 weeks and without interferon, achieved a 100% sustained viral response in all 40 patients with genotype 2 or 3 HCV. No viral breakthrough. No relapse. Every patient cleared the virus. Over 80% of patients had undetectable virus at just two weeks, and all were undetectable by week three. A separate trial, PROTON, showed 100% SVR in 24 of 24 patients who completed treatment, again with no breakthrough or relapse.
To understand why these numbers electrified the field, you need to know what HCV treatment looked like at the time. The standard of care was 24 to 48 weeks of pegylated interferon plus ribavirin, a regimen that caused flu-like symptoms, depression, anemia, and severe fatigue for months. Cure rates were around 40% to 50% for genotype 1, the most common strain. Many patients simply refused treatment because the side effects were worse than the disease. An oral drug that cured 100% of patients in 12 weeks without interferon was not an incremental improvement. It was a different category of medicine.
Fifteen days after that data presentation, Gilead announced the acquisition. On November 21, 2011, Gilead agreed to pay $137 per share in cash, an 89% premium to Pharmasset’s closing price and a total deal value of $11 billion. Pharmasset had no revenue, a net loss of $91 million for the year, and $166 million in cash. Its lead drug was in Phase 2. Gilead’s CEO John Martin called it “an important and exciting opportunity” and pointed directly to the Phase 2 data as the catalyst.
The market thought Gilead had lost its mind. The stock dropped. Competitors scrambled: BMS acquired Inhibitex for $2.5 billion to get a rival nucleotide compound, but that drug was pulled from development in August 2012 after the FDA flagged heart and kidney toxicities. Gilead’s bet looked increasingly inspired.
The drug received FDA approval in December 2013 and generated over $10 billion in revenue in its first full year. Harvoni (ledipasvir/sofosbuvir), a single-tablet combination, launched in 2014 and pushed the combined HCV franchise past $19 billion in annual sales at its peak. The pricing became the most contentious issue in the pharmaceutical industry for years. Gilead set the price at $84,000 per treatment course, or $1,000 per pill. That drew Congressional investigations, Senate hearings, and public outrage. Gilead’s defense had several layers: the drug replaced liver transplants and lifetime interferon therapy, making it cost-effective on a per-patient basis. Gilead had also paid $11 billion for a company with zero revenue and a drug still in Phase 2, taking on the very real risk that the trials could have failed entirely. Pharmasset’s own pre-acquisition forecast had projected a $36,000 price per course, but that number didn’t account for the cost and risk of acquiring the company at a massive premium. None of this mattered politically. The backlash shaped the drug pricing debate for the next decade.
But the very efficacy that justified the price tag was also unwinding the market. Every cured patient was one fewer customer, and with cure rates above 90%, the pool of Hepatitis C patients was shrinking faster than new diagnoses could replenish it. HCV revenue peaked in 2015 and has declined every year since. The sofosbuvir franchise generated $1.3 billion in 2025, down from that $19 billion peak. Gilead had built the most effective Hepatitis C treatment in history and in doing so eliminated the market it was selling into. The Pharmasset acquisition paid for itself many times over, but it left Gilead with a lesson that would shape every major decision the company made afterward: breakthrough science and durable revenue don’t always go together.
The HIV Fortress
While the HCV franchise was booming and then declining, Gilead was quietly building one of the most dominant product franchises in pharmaceutical history.
The progression went like this: Viread (2001) gave way to Truvada (tenofovir/emtricitabine), which became both an HIV treatment backbone and the first FDA-approved PrEP medication in 2012. Gilead then developed TAF, a newer version of tenofovir with significantly better kidney and bone safety, and used it as the foundation for next-generation regimens. Descovy (FTC/TAF) replaced Truvada. Genvoya and then Biktarvy (bictegravir/FTC/TAF) became the flagship treatment.
Biktarvy launched in 2018 and has been on a trajectory that rivals any drug in pharma history:
| Year | Biktarvy Revenue | YoY Growth |
|---|---|---|
| 2020 | $7.26B | +38% |
| 2021 | $8.61B | +19% |
| 2022 | $10.28B | +19% |
| 2023 | $11.85B | +15% |
| 2024 | $13.41B | +13% |
| 2025 | $14.33B | +7% |
Biktarvy holds over 50% of the U.S. HIV treatment market. In 2025, Gilead settled patent litigation with generic manufacturers Lupin, Cipla, and Laurus Labs, and the terms were favorable: no generic entry is expected in the U.S. before April 1, 2036, extending the effective exclusivity window by roughly two years beyond prior estimates.
Descovy, meanwhile, has surged in the PrEP market. Revenue grew 31% to $2.76 billion in 2025 as Descovy captured over 40% of U.S. PrEP prescriptions. Truvada, the older PrEP option, went generic in 2020, but patients and providers have largely shifted to Descovy based on the improved safety profile.
The most strategically significant HIV product is Yeztugo (lenacapavir), a twice-yearly injectable for PrEP that launched in 2025. This is the first long-acting injectable PrEP option, requiring just two shots per year instead of a daily pill. Gilead partnered with the U.S. State Department and PEPFAR to deliver lenacapavir PrEP to up to two million people over three years in low-income countries. Lenacapavir also has multiple ongoing Phase 3 trials as a treatment backbone in combination with other agents.
In total, HIV product sales reached $20.75 billion in 2025, up 6% year-over-year. That is 71% of Gilead’s total product revenue.
$30 Billion in Acquisitions: Building the Second (and Third) Act
Gilead’s M&A history since 2017 reads like a company trying to outrun the clock on a single-franchise business model.
Kite Pharma ($11.9 billion, 2017): Gilead entered the CAR-T cell therapy space by acquiring Kite, which had Yescarta (axicabtagene ciloleucel) in late-stage development for large B-cell lymphoma. Yescarta was approved in 2017 and generated $1.50 billion in 2025, though revenue declined 5% year-over-year amid competition from BMS’s Breyanzi and Novartis’s Kymriah, plus newer entrants. Kite also markets Tecartus for mantle cell lymphoma ($344 million, down 15%).
Immunomedics ($21 billion, 2020): Gilead’s largest acquisition brought Trodelvy (sacituzumab govitecan), an antibody-drug conjugate for metastatic triple-negative breast cancer. At $21 billion for a drug with then-modest revenue, this was the most expensive ADC deal in history. Trodelvy reached $1.40 billion in 2025 sales (+6%), but the story has been mixed. In 2024, the EVOKE-01 trial testing Trodelvy in second-line non-small cell lung cancer failed, triggering a $4.18 billion impairment charge that cratered Gilead’s annual earnings. First-line breast cancer trials are ongoing, and BLAs are filed for PD-L1 positive and PD-L1 negative mTNBC in combination with pembrolizumab.
CymaBay Therapeutics ($3.9 billion, 2024): This brought Livdelzi (seladelpar) for primary biliary cholangitis, a chronic liver disease. Livdelzi was approved in the U.S. in 2024 and the EU in 2025, adding a new growth vector in liver disease outside of viral hepatitis.
Arcellx (~$7.8 billion, February 2026): Gilead agreed to acquire Arcellx at $115 per share in cash plus a CVR worth $5 per share if anitocabtagene autoleucel (anito-cel) reaches $6 billion in cumulative worldwide sales by December 31, 2029. Gilead already held shares from a prior collaboration, so net new cash is roughly $7.0 billion. Anito-cel is a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma, competing directly with Johnson & Johnson/Legend Biotech’s Carvykti. The FDA accepted the BLA simultaneously with the deal announcement, with a decision expected mid-2026.
Ouro Medicines (~$2.175 billion, March 2026): Gilead agreed to acquire Ouro for $1.675 billion upfront plus $500 million in milestones. The key asset is OM336 (gamgertamig), a clinical-stage BCMAxCD3 T-cell engager designed for rapid, deep B-cell depletion after a limited subcutaneous treatment course. It targets autoimmune diseases. In an unusual structure, Galapagos NV (in which Gilead holds a significant equity stake from a 2019, $5.1 billion investment) will shoulder 50% of costs and absorb Ouro’s operating assets and personnel, leading R&D through the start of registrational studies. Gilead retains worldwide commercialization rights (except China) and would pay Galapagos royalties of 20% to 23% of net sales.
The Ouro deal puts Gilead back in familiar territory: developing a short treatment course designed to functionally cure a disease rather than manage it for life. That is the Sovaldi model all over again, and it raises a question that extends well beyond Gilead’s balance sheet. The pharmaceutical industry’s economic model rewards treatments that patients take indefinitely. A daily pill for a chronic condition creates a predictable, recurring revenue stream that Wall Street can model and investors can value. A cure creates a one-time transaction and a shrinking market. Gilead lived this firsthand when its HCV franchise fell from $19 billion to $1.3 billion precisely because the drugs worked too well.
The incentives are misaligned in a way that should bother everyone: companies that develop cures are financially punished for their own success, while companies that develop lifetime maintenance therapies are rewarded. How many potential cures have been quietly deprioritized because the commercial model didn’t support them? What would the drug development landscape look like if we properly rewarded companies for eliminating diseases entirely? Gilead, to its credit, keeps making these bets anyway. Whether gamgertamig works at scale is an open scientific question, but the willingness to pursue curative medicine despite the commercial headwinds is worth acknowledging.
The Financial Profile
Revenue and Profitability
Gilead’s financial statements for the three years ended December 31, 2025, tell a story of a stable, high-margin core business overlaid with lumpy acquisition-related charges.
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Revenues | $29.44B | $28.75B | $27.12B |
| Product Sales | $28.92B | $28.61B | $26.93B |
| Cost of Goods Sold | $6.23B | $6.25B | $6.50B |
| Gross Margin | 78.4% | 78.2% | 75.8% |
| R&D Expense | $5.80B | $5.91B | $5.72B |
| Acquired IPR&D | $1.02B | $4.66B | $1.16B |
| IPR&D Impairments | $590M | $4.18B | $50M |
| SG&A | $5.77B | $6.09B | $6.09B |
| Operating Income | $10.02B | $1.66B | $7.61B |
| Interest Expense | $1.02B | $977M | $944M |
| Net Income | $8.51B | $480M | $5.67B |
| Diluted EPS | $6.78 | $0.38 | $4.50 |
| Non-GAAP EPS | $8.15 | $4.60 | $7.02 |
The 2024 numbers look alarming until you understand what happened. Gilead booked a $3.8 billion acquired IPR&D charge from the CymaBay acquisition (these are expensed immediately under GAAP when acquired programs haven’t yet reached regulatory approval) and a $4.18 billion impairment on Trodelvy-related intangible assets after the lung cancer trial failure. Those two items totaled roughly $8 billion in non-cash charges and explain why net income dropped from $5.67 billion to $480 million while the underlying business was essentially flat.
In 2025, operating income rebounded to $10 billion as those charges didn’t repeat. The $590 million IPR&D impairment in 2025 related to Hepcludex (bulevirtide for Hepatitis Delta), where competitive market data weakened the commercial outlook outside the EU. The $1.02 billion in acquired IPR&D was primarily from the Interius BioTherapeutics acquisition for an in vivo CAR-T program.
The Margin Structure
Gilead’s gross margin of 78.4% is typical for a branded pharmaceutical company. R&D spending runs at roughly 20% of revenue ($5.80 billion in 2025), which is appropriate for a company running dozens of clinical programs across three therapeutic areas. SG&A declined to $5.77 billion from $6.09 billion, reflecting efficiency gains and restructuring.
Balance Sheet and Debt
| Dec 31, 2025 | |
|---|---|
| Cash and Cash Equivalents | $7.56B |
| Marketable Debt Securities (Short + Long-term) | $3.04B |
| Total Liquid Assets | $10.6B |
| Total Assets | $59.02B |
| Goodwill | $8.30B |
| Intangible Assets (net) | $16.99B |
| Senior Unsecured Notes | $23.83B |
| Stockholders’ Equity | $22.62B |
The balance sheet carries the weight of Gilead’s acquisition history. Goodwill ($8.3 billion) and intangible assets ($17 billion net) together account for $25.3 billion of $59 billion in total assets. The intangible assets are amortized at roughly $2.4 billion per year, which flows through cost of goods sold and depresses GAAP earnings relative to cash earnings.
The debt load of $23.83 billion is significant but manageable given the cash generation. The maturity schedule is well-structured: $2.75 billion was due in March 2026, $2.0 billion due in 2027, and then no major maturities until 2029. Interest rates range from 1.2% (2020 vintage) to 5.65% (2011 vintage), with most of the stack carrying coupons in the 2% to 5% range. Annual interest expense is $1.02 billion.
Net debt (total debt minus liquid assets) is roughly $13.2 billion.
Cash Flow and Capital Allocation
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating Cash Flow | $10.02B | $9.07B | $9.36B |
| Capital Expenditures | $563M | $528M | $583M |
| Free Cash Flow (est.) | $9.46B | $8.54B | $8.78B |
| Dividends Paid | $4.00B | $3.93B | $3.83B |
| Share Repurchases | $1.92B | $1.86B | $2.45B |
| Debt Repayment | $1.79B | $2.60B | $2.50B |
Gilead’s capital allocation priorities are clear: dividends first, then buybacks and debt reduction, with periodic large acquisitions funded by cash on hand and new debt issuance. The quarterly dividend as of February 2026 is $0.82 per share ($3.28 annualized), representing a payout of roughly 40% of free cash flow. Share repurchases have been modest but consistent, totaling $6.2 billion over three years. The share count has declined from 1.26 billion to 1.24 billion diluted shares over that period.
Management has been paying down debt while simultaneously executing acquisitions, keeping the net debt level relatively stable. With the Arcellx and Ouro deals adding roughly $8.7 billion in near-term cash commitments (net of Galapagos’s 50% share on Ouro), expect the cash balance to decline and potentially new debt to be issued in 2026.
What Could Go Wrong
Most of the obvious risks have already surfaced in this post: the Trodelvy lung cancer failure, the $4.2 billion impairment, the HCV revenue cliff. But there are a few structural issues worth sitting with.
The first is concentration. HIV is 71% of product sales. Biktarvy alone is half of total revenue. The 2036 patent settlement buys time, but a decade is shorter than it sounds when you’re trying to build entirely new franchises in oncology and autoimmune disease from acquired assets. If any of the major pipeline bets fail, Gilead in 2036 looks a lot like Gilead in 2016: scrambling to replace a declining franchise.
The second is pricing pressure. Rebates, chargebacks, and other deductions consumed 41% of Gilead’s gross product sales in 2025, up from 38% the prior year. The Medicare Part D redesign is the primary driver, and it’s still phasing in. Gilead can grow prescription volume and still see net revenue per prescription decline. For a company that generates 74% of its revenue in the U.S., domestic pricing policy is an existential variable.
The third is the TDF litigation. Roughly 23,000 individual plaintiffs allege that Gilead delayed the development of TAF (the safer successor to TDF) while continuing to sell TDF-based products like Viread and Truvada, causing kidney and bone injuries. The financial exposure is unquantified, but the plaintiff class is large and the core allegation (that Gilead had TAF data earlier than it acted on it) is the kind of narrative that plays well in front of a jury. This is a low-probability, high-impact risk that doesn’t show up in the earnings model until it does.
Valuation
Gilead generates consistent, high-quality free cash flow against a stable but slowly growing revenue base. The valuation challenge is assigning appropriate credit for the pipeline and future growth while accounting for the HIV concentration risk and the declining Veklury franchise.
Method 1: Earnings Multiple
Gilead’s GAAP earnings are distorted by acquisition-related charges that vary wildly year to year. Non-GAAP EPS strips those out and provides a better picture of steady-state earning power, which sits in the $8.00 to $8.50 range based on 2025 actuals ($8.15) and 2026 guidance ($8.45 to $8.85). Large-cap pharma companies with moderate growth, strong cash flow, and significant patent protection typically trade at 12x to 18x forward earnings, depending on pipeline optionality and growth visibility.
| Scenario | Multiple | Non-GAAP EPS | Per Share Value |
|---|---|---|---|
| Bear | 13x | $8.00 | $104 |
| Base | 16x | $8.50 | $136 |
| Bull | 19x | $8.65 | $164 |
The bear case assumes modest pipeline disappointments, continued gross-to-net erosion, and the market treating Gilead as a mature, ex-growth pharma. The base case reflects stable HIV growth, successful Trodelvy label expansion, and anito-cel approval. The bull case gives credit for lenacapavir becoming a transformational long-acting HIV platform, successful CAR-T expansion into myeloma, and early autoimmune pipeline validation.
Method 2: Discounted Cash Flow
Starting assumptions: - 2025 Free Cash Flow: $9.46B - Years 1 to 5 growth rate: 4% (HIV franchise grows mid-single digits, offset by Veklury decline and pipeline ramp) - Years 6 to 10 growth rate: 2% (maturation, generic risk approaching) - Terminal growth rate: 2% - Discount rate (WACC): 9%
| Year | FCF |
|---|---|
| 2026 | $9.84B |
| 2027 | $10.23B |
| 2028 | $10.64B |
| 2029 | $11.07B |
| 2030 | $11.51B |
| 2031 | $11.74B |
| 2032 | $11.98B |
| 2033 | $12.22B |
| 2034 | $12.46B |
| 2035 | $12.71B |
| Terminal Value | $185.2B |
| Value | |
|---|---|
| PV of FCF (Years 1-10) | $72.1B |
| PV of Terminal Value | $78.2B |
| Enterprise Value | $150.3B |
| Less: Net Debt ($13.2B) | -$13.2B |
| Equity Value | $137.1B |
| Shares Outstanding | 1.241B |
| Per Share | $111 |
Sensitivity analysis on discount rate and terminal growth:
| Terminal Growth 1.5% | Terminal Growth 2.0% | Terminal Growth 2.5% | |
|---|---|---|---|
| WACC 8% | $131 | $143 | $158 |
| WACC 9% | $108 | $111 | $125 |
| WACC 10% | $91 | $97 | $104 |
The DCF is sensitive to terminal value assumptions, which is typical for a company where the terminal year is post-Biktarvy patent cliff. If Gilead’s pipeline delivers new growth drivers by then, the terminal growth rate is conservative. If the pipeline disappoints, even 2% may be generous.
Method 3: Sum-of-the-Parts
This approach values each business segment separately and adds pipeline optionality.
| Segment | 2025 Revenue | EV/Revenue Multiple | Segment Value |
|---|---|---|---|
| HIV Franchise | $20.75B | 7.0x | $145.3B |
| Liver Disease | $3.22B | 4.0x | $12.9B |
| Oncology (Trodelvy + CAR-T) | $3.24B | 4.5x | $14.6B |
| Veklury | $911M | 1.0x | $0.9B |
| Other | $799M | 2.0x | $1.6B |
| Pipeline Optionality* | $15.0B | ||
| Enterprise Value | $190.3B | ||
| Less: Net Debt | -$13.2B | ||
| Equity Value | $177.1B | ||
| Per Share | $143 |
*Pipeline optionality includes anito-cel (risk-adjusted at $8B if approved, probability-weighted at 70% = $5.6B), Trodelvy label expansions ($4B risk-adjusted), lenacapavir franchise extensions ($4B), and early-stage inflammation/autoimmune programs ($1.4B).
The 7x revenue multiple on HIV reflects the franchise’s durability (patent protection through 2036), dominant market share, and lenacapavir’s long-acting optionality. The lower multiples on oncology and liver disease reflect competitive risk and the earlier-stage revenue trajectories.
Valuation Summary
| Method | Bear | Base | Bull |
|---|---|---|---|
| Earnings Multiple | $104 | $136 | $164 |
| DCF (WACC/Terminal Growth) | $91-108 | $111-143 | $125-158 |
| Sum-of-the-Parts | $143 | ||
| Composite Range | $100-110 | $130-145 | $155-165 |
The base case value is roughly $130 to $145 per share. The bear case, reflecting pipeline failures, accelerated gross-to-net erosion, and the market treating Gilead as a mature yield stock, puts a floor in the $100 to $110 range. The bull case, with successful pipeline execution across HIV, oncology, and autoimmune, pushes toward $155 to $165.
The biggest swing factor is whether Gilead’s $30+ billion in oncology and autoimmune acquisitions generate acceptable returns. If anito-cel, Trodelvy expansions, and gamgertamig all deliver, the upper end of the range is conservative. If they don’t, the company remains a highly profitable but narrowly concentrated HIV business that the market will value accordingly.
If you found this helpful, consider supporting my work. This blog has no ads and no paywalled content, and reader support is how it stays that way. You can also subscribe to my mailing list to get new deep dives in your inbox.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Anito-cel FDA decision | Approval would validate the $7.8B Arcellx deal and open the multiple myeloma market | Mid-2026 |
| Trodelvy 1L mTNBC FDA decisions | Two BLAs pending (PD-L1 positive and negative); success expands TAM significantly | 2026 |
| Hepcludex BLA FDA decision | U.S. approval for HDV would add a new growth vector in liver disease | 2026 |
| Arcellx tender offer closing | Extended to April 2026; regulatory clearance needed | April 2026 |
| Q1 2026 earnings | First look at Yeztugo (lenacapavir PrEP) uptake trajectory and 2026 guidance tracking | Late April 2026 |
| BIC/LEN regulatory filing | Next-generation HIV oral combo filing would signal Biktarvy succession planning | 2026-2027 |
| Gross-to-net deduction trends | 38% to 41% in one year; continued expansion compresses net revenue per prescription | Ongoing quarterly |
| Ouro/Galapagos deal closure | Unusual cost-sharing structure; watch for integration and Galapagos execution | Mid-2026 |
| Biktarvy patent settlement compliance | 2036 generic entry date is the most important single number in Gilead’s financial model | Ongoing |
| OM336 registrational study design | Will reveal target indications, trial size, and timeline for autoimmune market entry | 2026-2027 |
Sources:
- 10-K filed February 24, 2026
- 8-K filed February 23, 2026 (Arcellx Merger Agreement)
- 8-K filed February 10, 2026 (Q4 2025 Earnings)
- 8-K filed October 6, 2025 (Lenacapavir PrEP/PEPFAR)
- 8-K filed November 20, 2024 (Debt Agreement)
- Gilead Press Release: Ouro Medicines Acquisition, March 23, 2026
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.